ROBIN HOUSE: Open Payments
NPI 1003008095 · LONDON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,938 in 128 payments from 14 companies in 2025. Trend: 2023 $1,525 · 2024 $5,405 · 2025 $1,938
Food & beverage: $1,938
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $473 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 31 | $437 |
| Madrigal Pharmaceuticals | 8 | $240 |
| Aimmune Therapeutics, Inc. | 13 | $164 |
| Ardelyx, Inc. | 11 | $151 |
| Phathom Pharmaceuticals, Inc. | 12 | $99 |
| Gilead Sciences, Inc. | 3 | $76 |
| Novartis Pharmaceuticals Corporation | 4 | $67 |
| GENZYME CORPORATION | 3 | $55 |
| QOL Medical, LLC | 2 | $52 |
Products named: XIFAXAN, REZDIFFRA, MAVYRET, LINZESS, IBSRELA, ZENPEP, VOQUEZNA, LEQVIO.
Industry payments across KY — which companies pay providers there.
